Skip to content

Cervicogenic headache (the nerve entrapment) treated by acupotomy: a randomized controlled trial

Clinical application of acupotomy in the treatment of cervical headache (nerve entrapment type)

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800018677
Enrollment
Unknown
Registered
2018-10-03
Start date
2018-12-01
Completion date
Unknown
Last updated
2019-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical headache

Interventions

Group 1:acupotomy combined with sham nerve block treatment
Group 2: nerve block combined with sham acupotomy

Sponsors

Department of acupuncture-moxibustion, China-Japan Friendship Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1) Comply with the latest revised diagnostic criteria (2013 edition) diagnostic criteria published by the International Headache Association (HIS); 2) Aged 18-70 years old; 3) VAS score > 3 points; 4) Voluntary signing of informed consent.

Exclusion criteria

Exclusion criteria: 1) If the treatment is not carried out according to the regulations, it is impossible to determine the efficacy or incomplete data and other factors that affect the efficacy; 2) Patients taking headache treatment within 2 weeks before treatment, such as analgesics or non-steroidal anti-inflammatory drugs, hormone drugs, etc.; 3) Prevent the safe participation of the experimental design and the disease that affects the study, such as myocardial infarction or stroke, congestive heart failure, severe chronic obstructive pulmonary disease, cancer, diabetes, severe systemic disease and seriousness in the past 3 months Psychosis; imaging examination of intracranial and external organic lesions, such as neck tumors, tuberculosis, infection, fracture and dislocation. Unilateral headaches were diagnosed as other headaches such as cluster headaches and tension headaches; 4) patients who are receiving other related treatments that may affect the observation of the effect indicators in this study; 5) a history or clinical manifestation of bleeding tendency, including the use of anticoagulants; 6) Pregnant women and lactating women; 7) Participate in other research at the same time; 8) unable to complete the filling of various scales.

Design outcomes

Primary

MeasureTime frame
VAS visual simulation score;

Secondary

MeasureTime frame
SF-36 scale Chinese version score;

Countries

China

Contacts

Public ContactShiliang Li

China-Japan Friendship Hospital

zrlishiliang@163.com+86 010 84205344

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026